UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported):
May 5, 2006
|
ImmunoGen,
Inc.
|
||||
|
(Exact
name of registrant as specified in its charter)
|
||||
|
|
|
|
|
|
|
Massachusetts
|
0-17999
|
04-2726691
|
||
|
(State
or other
|
(Commission
|
(IRS
Employer
|
||
|
jurisdiction
of
|
File
Number)
|
Identification
No.)
|
||
|
incorporation)
|
||||
|
|
|
|
|
|
|
128
Sidney Street, Cambridge, MA 02139
|
||||
|
(Address
of principal executive offices) (Zip Code)
|
||||
|
|
|
|
|
|
|
Registrant’s
telephone number, including area code:
(617) 995-2500
|
||||
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
ITEM
5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS.
| (a) |
Not
applicable
|
| (b) |
and
(c)
|
Effective
May 5, 2006, Karleen M. Oberton, Senior Corporate Controller and Principal
Accounting Officer of ImmunoGen, Inc., has resigned her position to accept
a
position with another company.
Daniel
M.
Junius, the Company’s Senior Vice President, Finance and Chief Financial
Officer, will serve as ImmunoGen’s Principal Accounting Officer effective
immediately while ImmunoGen
conducts a search for a new Corporate Controller. Mr. Junius has been with
the
Company since May 2005.
Prior to
joining ImmunoGen, Mr. Junius served as Executive Vice President and Chief
Financial Officer of New England Business Service (NEBS) from 1998 until 2004.
Prior to NEBS, Mr. Junius was Vice President and Chief Financial Officer at
Nashua Corporation, which he joined in 1984 and held financial management
positions of increasing responsibility before becoming Chief Financial Officer
in 1996. Mr. Junius has entered into no transactions with ImmunoGen of the
kind
that would require disclosure under Item 404(a) of Regulation S-K.
As
previously disclosed, Mr. Junius’ base salary is $300,000 per year, and he is
eligible for an annual cash bonus of up to 35% of his annual salary. Mr. Junius
is entitled to receive severance payments in an amount equal to twelve (12)
months of his annual base salary in effect immediately prior to termination,
in
the event that his employment is terminated by the Company without
cause.
(d)
Not
applicable
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ImmunoGen,
Inc.
|
|||
|
(Registrant)
|
|||
|
|
|
|
|
|
Date:
May 10, 2006
|
/s/
Daniel M. Junius
|
||
|
|
|
|
|
|
Daniel
M. Junius
|
|||
|
Senior
Vice President and Chief Financial Officer
|
|||
3